Merck's Deal Chief Hints at Continued Acquisitions Ahead of Keytruda's Patent Expiry
Merck's CEO has been actively pursuing deals to strengthen its pipeline as the patent on its blockbuster drug Keytruda approaches expiration. The company's top dealmaker now signals that further mergers and acquisitions are likely on the horizon. This strategy aims to offset the expected revenue decline from Keytruda's loss of exclusivity.
Expanded Detail
EXPANDED:
Merck's leadership is strategically pivoting its corporate focus toward replenishing its drug portfolio. The impending loss of market exclusivity for its top-selling oncology treatment creates a significant financial
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Merck's top dealmaker signals more M&A as Keytruda's patent cliff nears.” Browse more stories.